Upstream Bio Stock

Upstream Bio EV/EBIT

The EV/EBIT (Enterprise Value to EBIT) of Upstream Bio (UPB) as of Aug 4, 2026 is -2.92. In the previous year, EV/EBIT (Enterprise Value to EBIT) was -6.02 — a change of -51.51% (higher).

EV/EBIT

-2.92

YoY

-51.51%

Last updated:

EV/EBIT (Enterprise Value to EBIT) of Upstream Bio is 2026 -2.92 . EV/EBIT (Enterprise Value to EBIT) of Upstream Bio was 2025 -6.02 . It decreases by -51.51% higher compared to the previous year.

The Upstream Bio EV/EBIT history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

PRICE-TO-EBIT
Date
PRICE-TO-EBIT
Jan 1, 2022
0.00 base
Jan 1, 2023
0.00 base
Jan 1, 2024
-10.85 base
Jan 1, 2025
-9.18 base
Jan 1, 2026 (e)
-167.90 base
YEARPRICE-TO-EBIT
2026 est -167.90
2025 -9.18
2024 -10.85
2023 -
2022 -
Access this data via the Eulerpool API

Upstream Bio Valuation

Details

Historical Valuation Multiples

Price-to-Earnings Ratio (P/E)

The P/E ratio divides Upstream Bio's share price by its earnings per share. It tells you how many years of current earnings you are "paying for" when you buy the stock. A P/E of 20 means you pay $20 for every $1 of annual earnings. The S&P 500 historically trades at an average P/E of roughly 15–17. A P/E significantly above that may signal high growth expectations; one below may indicate undervaluation — or declining business quality.

Price-to-Sales Ratio (P/S)

The P/S ratio divides market capitalization by total revenue. Unlike the P/E ratio, it works even for companies that are not yet profitable, making it essential for evaluating high-growth firms. A P/S below 1.0 may indicate undervaluation, while ratios above 10 are typically reserved for fast-growing tech or SaaS companies with high expected future margins.

Price-to-EBIT Ratio

This ratio relates Upstream Bio's market price to its operating earnings, excluding the effects of debt structure and tax jurisdiction. It is particularly useful for comparing companies across different countries or with different levels of leverage, because it focuses purely on operational profitability. Lower values suggest cheaper operational earnings.

How to Use This Chart

This chart plots Upstream Bio's valuation multiples over time. Compare the current P/E, P/S, and P/EBIT to their own historical averages — if the current ratio is well below the multi-year average, the stock may be relatively cheap compared to its own track record. Combine this with industry comparisons: a P/E that looks high in absolute terms may be justified if Upstream Bio grows earnings faster than its peers.

Upstream Bio Stock analysis

What does Upstream Bio do? Upstream Bio is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Upstream Bio stock

EV/EBIT (Enterprise Value to EBIT) of Upstream Bio is -2.92 in 2026.

EV/EBIT (Enterprise Value to EBIT) of Upstream Bio changed from -6.02 to -2.92, representing a -51.51% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of EV/EBIT (Enterprise Value to EBIT) Upstream Bio since 2006 – with annual values, charts, and detailed analysis.

The EV/EBIT ratio measures a company's enterprise value relative to its operating earnings. It accounts for debt, making it useful for comparing companies with different capital structures.

EV/EBIT = Enterprise Value / Earnings Before Interest and Taxes

To evaluate EV/EBIT (Enterprise Value to EBIT)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for EV/EBIT (Enterprise Value to EBIT).

A 'good' varies by industry and company stage. On Eulerpool, you can compare EV/EBIT (Enterprise Value to EBIT)'s Upstream Bio with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

Valuation — Upstream Bio

All Key Metrics — Upstream Bio